EUCTR2005-004761-42-ES
Active, not recruiting
Not Applicable
First line treatment with Rituximab asociated to CVP plus Interferon in Follicular Lymphoma. Phase II study.Asociación de Rituximab al esquema CVP + Interferón en el tratamiento de primera línea del linfoma folicular - R-CVP-IF
Fundacion Leucemia y Linfoma0 sitesDecember 12, 2005
DrugsMabThera®
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Fundacion Leucemia y Linfoma
- Status
- Active, not recruiting
- Last Updated
- 14 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Age \=18 and \= 75 years.
- •\- Grade 1 or 2 Follicular Lymphoma, Marginal Zone Lymphoma or Lymphocitic Lymphoma (with no CLL criteria) confirmed by nodal tissue. Patients with diagnosis made in bone marrow trephine will be accepted, if no adenopathy is detected and MCL or CLL are ruled out.
- •\- Follicular Lymphoma International Prognostic Index (FLIPI) \= 2\.
- •\- No prior chemotherapy of radiotherapy. Local radiation is accepted.
- •\- Adequate hepatic and renal function (acceted if related to LNH infiltration)
- •\- Correct Thyroid function
- •\- ECOG performance status 0 to 3\.
- •\- Abscence of other malignancies or impariment to receive thge drugs in the study.
- •\- Signed approved informed consent before any study specific procedures are performed.
- •Are the trial subjects under 18? no
Exclusion Criteria
- •\- Prior chemotherapy of radiotherapy.
- •\- Active second malignancy in the previous 5 years.
- •\- Previous Psiquiatric disease, specially moderate to severe depression, psycosis, autolytic attempts.
- •\- Uncontrolled current cardiopathy (myocardial infarction, angina, significant cardiac arrythmia or congestive heart failure)
- •\- Diabetes mellitus insulin requirement.
- •\- Uncontrolled hepatic or autoimmune disease.
- •\- Female subjects who are breast\-feeding
- •\- Female subjects, who are not surgically sterile or post\-menopausal, and do not use medically acceptable methods of birth control for the duration of the study and for one year after the last dose.
- •\- Acute or ongoing chronic infectious disease.
- •\- Immunocopromised subjects including subjects known to be HIV possitive or acute/chronic HCV or HBV positive.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
A phase II study of the combination of Rituximab, Mitoxantrone, Etoposide, and Prednisolone for relapsed elderly patients with diffuse large B-cell lymphoma (R-MEP07)Diffuse large B-cell lymphomaJPRN-UMIN000001050Clinical Hematology Study Group of National Hospital Organization (CHSG-NHO)40
Active, not recruiting
Not Applicable
First line treatment with rituximab plus fludarabine, cyclophosphamide, mitoxantrone (R-FCM) and maintenance therapy with rituximab in patients diagnosed with chronic lymphocytic leukemia. Tratamiento de primera línea con rituximab combinado con fluradabina, ciclofosfamida y Mitoxantrone (R-FCM) y mantenimiento con rituximab de pacientes con leucemia linfática crónica (LLC) - R-FCM in CPatients diagnosed with chronic lymphocytic leukemia (CLL) according to the WHO guidelines, within 18 and 71 years and not previously treatedEUCTR2005-001569-33-ESDept. Hematology, Hospital Clinic60
Active, not recruiting
Not Applicable
Brief induction chemoimmunotherapy with Rituximab + Bendamustine + Mitoxantrone followed by Rituximab in elderly patients with advanced stage previously untreated follicular lymphoma - IILFLE09EUCTR2009-012337-29-ITFONDAZIONE ITALIANA LINFOMI ONLUS
Completed
Phase 2
Phase II study of rituximab containing induction chemotherapy (R-high-CHOP followed by CHASER) and high-dose chemotherapy (LEED) supported with auto-PBSCT for previously untreated patients with advanced mantle cell lymphoma(JCOG0406)newly diagnosed advanced mantle cell lymphomaJPRN-UMIN000001220Japan Clinical Oncology Group(JCOG)45
Active, not recruiting
Phase 1
PHASE II STUDY OF CETUXIMAB FOR THE TREATMENT OF REFRACTORY OR RELAPSED MULTIPLE MYELOMA EMMA-1 (ERBITUX FOR MULTIPLE MYELOMA) - EMMA-1Relapsed or refractory multiple myelomaEUCTR2005-005612-24-DEniversity of Cologne